Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Oncolytics Biotech Inc. (ONCY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.73 | $6.63 | $2.22 | 359.22% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Oncolytics Biotech Inc. comes to $4.73. The forecasts range from a low of $2.22 to a high of $6.63. The average price target represents an increase of 359.22% from the last closing price of $1.03.
Analyst Price Targets (6 )
Broker Rating
Oncolytics Biotech Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 57.14% and 42.86% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 42.86%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ONCY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/10/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
4/4/2024 | Raymond James Ltd. | Rahul Sarugaser | Not Available | Moderate Buy |
3/8/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/8/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
2/8/2024 | Canaccord Genuity | John L Newman | Strong Buy | Strong Buy |
2/2/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
10/17/2023 | Leede Jones Gable | Douglas W Loe | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $4.73 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | -0.08 |